Vascular access in Cystic Fibrosis - Does Size Matter?
Authors:
- 1 April 2005
- journal article
- research article
- Published by SAGE Publications in The Journal of Vascular Access
- Vol. 6 (2) , 72-75
Abstract
Vascular access is an important part of patient management in cystic fibrosis. In most instances, vascular access is straightforward. However, a single bad experience with venepuncture has a lasting impact. Clinical experience suggested that for some individuals a smaller, shorter intravenous catheter (Leaderflex 22G, 0.7 mm × 8.0 cm, Vygon) might be a suitable alternative to standard vascular access via a standard long-line (2 Fr or 3 Fr Nutriline, Vygon). Methods: Between September 2002 and May 2004 we offered a free, fully informed choice between a standard 30 cm long line or a shorter (8 cm) Leaderflex line and audited this change in practice. Results: A total of 56 lines were inserted over the study period. Data were available for 54 of these (22 Leaderflex and 32 standard long lines). Mean and median line survival was comparable. Leaderflex lines survived for a mean of 12.2 days and median of 14 days. Standard long lines survived for a mean of 12.6 days and median of 14 days. Discussion: Leaderflex lines offer a well-tolerated alternative to standard long lines for the administration of a 14-day course of intravenous antibiotics. Their reduced size and cost offer advantages to patients and doctors.Keywords
This publication has 5 references indexed in Scilit:
- Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosisPediatric Pulmonology, 2003
- Totally implantable venous access devices in children with cystic fibrosis: incidence and type of complicationsThorax, 1998
- The Impact of Previous Experience on Children's Reactions to VenepuncturesJournal of Health Psychology, 1998
- Peripheral Intravenous Line Survival and Phlebitis Prevention in Patients Receiving Intravenous Antibiotics: Heparin/Hydrocortisone versus In-Line FiltersAnnals of Pharmacotherapy, 1994
- TOTALLY IMPLANTABLE VASCULAR ACCESS IN TREATMENT OF CYSTIC FIBROSISThe Lancet, 1986